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ABSTRACT This review focuses on the methods available for measuring reversible airways obstruction,
bronchial hyperresponsiveness (BHR) and inflammation as hallmarks of asthma, and their role in
monitoring children with asthma. Persistent bronchial obstruction may occur in asymptomatic children
and is considered a risk factor for severe asthma episodes and is associated with poor asthma outcome.
Annual measurement of forced expiratory volume in 1 s using office based spirometry is considered useful.
Other lung function measurements including the assessment of BHR may be reserved for children with
possible exercise limitations, poor symptom perception and those not responding to their current
treatment or with atypical asthma symptoms, and performed on a higher specialty level. To date, for most
methods of measuring lung function there are no proper randomised controlled or large longitudinal
studies available to establish their role in asthma management in children.
Noninvasive biomarkers for monitoring inflammation in children are available, for example the
measurement of exhaled nitric oxide fraction, and the assessment of induced sputum cytology or
inflammatory mediators in the exhaled breath condensate. However, their role and usefulness in routine
clinical practice to monitor and guide therapy remains unclear, and therefore, their use should be reserved
for selected cases.
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Introduction
Current guidelines recommend tailoring of asthma management according to disease control, which is
generally defined by symptoms and, to a lesser extent, lung function and markers of airway inflammation.
Recently, a European Respiratory Society (ERS) Task Force on Monitoring Asthma in Childhood was
published [1]. As reversible airways obstruction, bronchial hyperresponsiveness (BHR) and chronic airways
inflammation are hallmarks of asthma, this review focuses on available methods for and the usefulness of
measuring lung function, bronchial responsiveness and inflammation when monitoring children with asthma.
Three other articles in this issue of the European Respiratory Review will address general considerations for
monitoring asthma in children, monitoring symptoms, exacerbations and quality of life, and
management-related issues [2–4].
Lung function
In children with asthma periodic objective assessment of pulmonary function is necessary to optimise
management and ensure that therapeutic goals are being achieved. Significant bronchial obstruction may
be present in asymptomatic asthmatic children and it has been shown that children with chronic airway
obstruction are less likely to perceive dyspnoea compared with children with acute obstruction [5, 6].
Children with poor perception of bronchial obstruction may be at higher risk of developing severe asthma
episodes and reduced lung function is associated with poor asthma outcomes [7]. Therefore, regular
assessment of lung function seems logical in monitoring of children with asthma. However, only 20–40%
of primary care providers use lung function measurements in asymptomatic asthmatic patients and up to
59% of paediatricians never perform lung function tests [8–11].
Maximal flow–volume curves
Maximal expiratory flow–volume curves are considered the gold standard for the assessment of lung
function in children with asthma. Regular assessment of pre- and post-bronchodilator forced expiratory
volume in 1 s (FEV1) might help to identify children at risk for developing a progressive decline in airflow.
Epidemiological studies have consistently shown a tracking of FEV1 and FEV1/forced vital capacity (FVC)
ratio from childhood to adulthood [12, 13]. On a shorter timescale, FEV1 has been shown to be an
independent predictor of asthma exacerbations: asthmatic children with a baseline FEV1 <60% predicted
have a doubled risk for asthma exacerbations in the subsequent year as compared with children with an
FEV1 >80% predicted [14]. FEV1 is considered important in defining asthma severity [15, 16]. However,
many, if not most, school children have an FEV1 >80% predicted, hence within the accepted normal range
independent of their asthma severity when defined on the basis of symptoms [12, 13]. This indicates that
the cut-off values may not adequately stratify asthmatic children [12]. Regular spirometry every 1–2 years
has been recommended for children with asthma who are ⩾5 years of age by the National Asthma
Education and Prevention Program (NAEPP) guidelines [16].
In children younger than 7 years of age, FEV1 may not be sensitive and may have a different physiological
meaning as compared with older children [17]. However, there is insufficient data on the value of
parameters of more peripheral airways, such as the forced expiratory flow at 50% of FVC (FEF50%) and/or
forced expiratory flow at 25–75% FVC (FEF25–75%), in the monitoring of asthma in children. A large,
retrospective cross-sectional analysis of the mean FEV1/FVC ratios from 4–18 years of age demonstrated a
steep and consistent decline with increasing age in asthmatic children suggesting the FEV1/FVC ratios
provide greater sensitivity in childhood asthma compared with FEV1 [18].
In general, both FEV1 and the FEV1/FVC ratio correlate poorly with symptom-based severity in children,
which may indicate that asthma management relying on reported symptoms only may be insufficient [19,
20]. To date, there is no randomised controlled trial comparing monitoring of symptoms only to
monitoring of symptoms plus FEV1 in asthmatic children.
While single FEV1 measurements may not reflect the inherent variability of the disease, home
measurements using small, electronic hand-held devices may allow day-to-day monitoring of lung
function. Data on the added value of regular home lung function measurement are conflicting. FEV1
values obtained by home spirometry over a period of 8 weeks were significantly lower on days with asthma
symptoms compared with symptom free days; however, the distribution of FEV1 values showed complete
overlap between symptomatic and asymptomatic days in individual patients [21]. The clinical value of
home FEV1 measurements was reduced by a steady reduction in compliance and in the validity of the data
over the study period, with wide individual differences [22]. Manoeuvre quality was influenced by age,
treatment and region, and was lower in children with FEV1 <80% predicted [23]. BROUWER et al. [21]
showed very high variability of FEV1 values over a 3-month period in asthmatic children with a poor
concordance to other indices of disease activity.
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In summary, in children with asthma >5 years of age the evidence indicates that it is useful to perform
office based spirometry at least annually, and more frequent assessments may be indicated depending on
the clinical course and the patient’s asthma severity. In patients in whom symptom-guided treatment is
difficult home spirometry might be useful, but should preferably be limited to a relatively short period of
observation. In children with severe asthma daily telemonitoring of FEV1 for 1 year did not reduce
exacerbation rates [24].
There is a need for proper randomised controlled studies to establish the role of regular spirometry in
asthma management in children. Studies should investigate the minimal or optimal frequency for the
assessment of flow–volume curves. The value of the measurement of peripheral airflow obstruction, i.e.
FEF50% and/or FEF25–75%, needs to be established as these parameters are likely to reflect the
pathophysiological processes in early asthma.
Reversibility testing
The response to bronchodilators demonstrating reversibility or airway obstruction is considered a key feature
of asthma and therefore consistent with the diagnosis of asthma. The American Thoracic Society (ATS)/ERS
recommendations define a significant bronchodilator response (BDR) as an increase in FEV1 ⩾12% and/or
⩾200 mL [25]. Children with a persistent BDR are at greater risk of developing a progressive decline in lung
function, and have higher healthcare utilisation, lower asthma control and a more frequent need for oral
steroid bursts. However, a persistent BDR may also be associated with poor treatment compliance or poor
inhaler technique [26, 27]. The presence of a BDR in asthmatic children is correlated to measures of airway
inflammation, such as the exhaled nitric oxide fraction (FeNO), and is predictive for a positive response to
inhaled corticosteroids (ICSs) [28–30]. BDR tends to decrease over time indicating airway remodelling [31].
Based on the above, assessment of BDR in asthma monitoring is useful at a high specialty level. As there
are variable influences on BDR, it is pertinent that the BDR test is performed as recommended [25]. In
children with asthma with reduced FEV1 and loss of BDR (reduced post-BDR lung function) it is useful to
consider further investigations and follow-up in specialist care.
A properly conducted trial using BDR to alter treatment is needed to further establish the usefulness of
regular BDR measurement in clinical practice. It is still unclear which intervention should be undertaken
in asthmatic children with a loss of BDR. Longitudinal or large cross-sectional studies should be carried
out to assess age-specific response rates.
Measurement of peak flow
Regular monitoring of peak expiratory flow (PEF) is used widely in the management of patients with
asthma as this is a simple and inexpensive method. Measurements of PEF on a day-to-day basis may allow
monitoring of the variable airway obstruction, which is considered one of the key features of asthma and
the variability in PEF may be predictive of exacerbations [16, 32]. The mean day-to-day variability of peak
flow in healthy children is between 6.2% and 8.2%, with a 95th percentile of 12.3–31% [33, 34]. PEF has
been shown to correlate with FEV1, but this correlation worsens in asthmatic patients with airflow
limitation [35]. In a study in 40 asthmatic children the percentage of correct entries in a PEF diary was
only 56% during the first week and declined to <50% over the subsequent 4 weeks, with up to 50% of
entries being invented or falsified [36].
Several studies have assessed the added value of daily PEF measurements to asthma management driven
by symptom recognition in asthmatic children. One study found that patients who used PEF to guide
therapy when symptomatic had a lower asthma severity score, fewer symptom days and less healthcare
utilisation than children who either used PEF daily or evaluated subjective symptoms alone [37]. In an
uncontrolled study, in 77 asthmatic children, daily PEF in combination with comprehensive asthma
education resulted in a reduction in the number of asthma episodes, medical and emergency department
visits, and missed school days [38]. Two randomised controlled studies did not show a benefit of PEF
guided treatment compared with management based on symptoms alone, and addition of PEF did not
enhance self-management even during acute exacerbations [28, 39]. Therefore, routine PEF measurements
are not useful to monitor asthma in children.
Measurement of airway resistance
Interrupter resistance (Rint), impulse oscillometry (IOS) and the forced oscillation technique (FOT) assess
respiratory resistance as an indirect measure of airway obstruction [40]. As these techniques can be carried
out relatively independently of active collaboration they are suitable for preschool children [32, 41, 42].
While data on reference values are limited, these methods are reproducible and useful in the assessment of
the BDR and bronchial responsiveness [42–48]. The cut-off values to detect significant differences between
measurements are, however, variable [49, 50]. Longitudinal assessment of Rint did not improve the
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prediction of asthma symptoms until the age of 8 years [51]. IOS was compared with spirometry to assess
the long-term effects of three controller regimens in children with persistent asthma. Whereas spirometric
measures best reflected differences in controller therapy in the first 12 weeks of treatment, IOS was
superior from 12 to 48 weeks [52]. By contrast to FEV1, increased IOS indices were predictive of the loss
of asthma control and the area under the curve of baseline R5–20 Hz was 0.91 in the receiver operating
characteristic analysis for the prediction of asthma control status after 8–12 weeks in a recent study in
asthmatic children aged 7–17 years [53].
Despite Rint, IOS or FOT measurements having some potential as monitoring tools in preschool
asthmatics, to date, there are no longitudinal studies confirming their usefulness.
Body plethysmography
While in the majority of well-controlled asthmatic children flow–volume curves are sufficient for the
monitoring of the disease, body plethysmographic measurements of lung volumes (i.e. air trapping) and
compression-free forced expiratory flow–volume curves by use of “chest flow” from body plethysmography
may be of interest in the management of difficult and severe asthma [54]. Asthmatic children with lung
hyperinflation, defined as a residual volume of >120% predicted, had more daytime asthma symptoms and
lower body weight and body mass index, and 49% of children with airflow obstruction (FEV1/FVC <80%)
showed significant hyperinflation [55]. In a large study, including 2193 asthmatic children, specific airway
resistance was more strongly related to FEF50% than to FEV1, suggesting that specific airway resistance
may reflect early airway obstruction in children [56]. Specific airway resistance measured at preschool age
correlated with subsequent FEF50%; therefore, predicting subsequent mild airflow limitation. In obese
asthmatic children specific airway resistance measured by body plethysmography can be helpful in
differentiating lung function changes due to asthma (elevated specific airway resistance) from those due to
obesity (normal specific airway resistance) [57]. To date, there are no randomised controlled studies
showing that body plethysmography is useful in routine monitoring of asthma in children.
Interventional studies may establish the additional value of body plethysmographic parameters in altering
asthma treatment. It is still unclear which body plethysmographic values may predict short- and long-term
outcomes of asthma in children. In addition, the value of helium dilution spirometry needs to be assessed.
Multiple-breath gas washout techniques (lung clearance index)
The lung clearance index (LCI), derived from multiple-breath inert gas washout, measures overall
ventilation inhomogeneity. The advantages of LCI measurements are the narrow normal range and its
independence of age [58]. LCI has been shown to be a sensitive marker of early airway disease in children
with asthma and, in particular, in children with cystic fibrosis [59]. Scond (an index of conductive
ventilation inhomogeneity) is based on the contribution to phase III slope from differences in ventilation
distribution occurring in the conducting airway zone. A recent study in allergic asthmatic children found
elevated Scond, and a close correlation between Scond and increased levels of FeNO and the presence of BHR
[60]. In asthmatic school children baseline LCI was significantly higher when compared with healthy
age-matched controls indicating greater overall ventilation heterogeneity [61].
As appropriate studies are lacking, to date, there is no role for multiple-breath washout techniques in the
routine monitoring of children with asthma. The role of LCI in measuring early airway disease in children
with asthma requires further exploration. As there is now commercially available equipment for nitrogen
washout and for SF6 washout, future studies should aim to assess early asthma specific changes
longitudinally in preschool and school aged children. In addition, treatment responses and predictors of
the disease course should be a focus for future research.
Infant lung function
Different methods have been used to assess lung function in wheezy infants including the analysis of tidal
flow–volume breathing loops, forced expirations from either normal inspiration (rapid thoracic compression
technique) or from total lung capacity (raised volume rapid thoracic compression technique) or body
plethysmography [62–67]. Infant lung function testing has been used to assess phenotypes in infants with
wheezing and to develop prediction models for persistent asthma [68]. Reduced lung function and/or BHR
in infancy were associated with persistent wheezing phenotypes, and with reduced lung function and asthma
at school age [62, 67–70]. In addition, reduced lung function was predictive for wheezy symptoms in the
following years [61, 71–73]. Reduced lung function in infancy was associated with respiratory morbidity and
treatment needs at preschool age [65]. Some studies showed improvement of lung function, such as forced
expiratory volume in 0.5 s, in infants with recurrent wheezing after ICS treatment or oral treatment with
montelukast, whereas others did not show significant changes [63, 64, 74, 75].
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To date, there is no role for infant lung function testing in the clinical monitoring of wheezing infants.
Future research should focus on methods for infant lung function testing that allow repeated
measurements in unsedated children.
Bronchial hyperresponsiveness
One major characteristic of asthma is the variability in bronchial tone in a response to a variety of
different stimuli.
BHR may be assessed by bronchial provocation tests and can be used both in research and as a means of
monitoring the severity of asthma. Bronchial provocation tests may be performed with different chemical
substances, such as histamine or methacholine (both of which are considered nonspecific direct
bronchoprovocation tests), or by inhaling allergens (specific direct bronchoprovocation tests) as well as by
using variety of stimuli such as physical exercise, inhaled cold air and hyperventilation with dry air (all of
which are indirect bronchial provocation tests) [76–83].
Determination the provocative concentration or dose causing a 20% reduction in FEV1 is used for
bronchoprovocation tests with methacholine, histamine and AMP, and may be used for allergen
bronchoprovocation tests [77, 84]. A bronchoprovocation test with inhaled mannitol was recently
developed and launched commercially in a test involving inhaling cumulative doses of mannitol through a
powder inhaler. In this test a 15% reduction in FEV1 is used as cut-off [83]. Although mannitol
provocation seems safe and feasible, even in young children, the specific role of mannitol provocation in
exploring BHR in asthmatic children needs further study [85]. Exercise testing is the most important
measure of indirect bronchial responsiveness. A reduction in FEV1 of at least 10% is taken as a sign of
exercise-induced bronchoconstriction. A correctly performed exercise test gives information about the
presence of exercise-induced bronchoconstriction as well as the motor development and fitness of the
child. In all international guidelines on treating asthma in childhood mastering exercise-induced asthma is
seen as a major objective in the treatment of asthma, with the exercise test as an important tool. The
standardisation of the exercise test is important with regard to environmental factors such as temperature,
humidity of the inhaled air and exercise load [86–88]. Running is the preferred exercise, and is most easily
standardised using a treadmill for a test of 6–8 min duration, reaching and maintaining an exercise load of
90–95% of the calculated maximum for the last 4 min of the test [88–90]. The sensitivity of the exercise
test can be increased by inhaling cold or dry air during exercise [91]. The exercise test can be used for the
diagnosis of exercise-induced bronchoconstriction, but also to assess the protective effect of asthma drugs
against exercise-induced bronchoconstriction.
With the diagnosis of asthma in mind, direct BHR is seen as the most sensitive measure of bronchial
asthma, whereas indirect measures of BHR are considered to be more specific and less sensitive [77].
Compared with exercise testing, methacholine bronchoprovocation tests are more sensitive, but markedly
less specific, to discriminate between asthma and other chronic lung diseases. When cold air inhalation
was added to the exercise test sensitivity comparable to methacholine test was reached, while maintaining
the sensitivity [91]. Indirect bronchoprovocation tests are rapidly influenced by treatment with inhaled
steroids with the first effects already appearing after 1 week, whereas methacholine bronchoprovocation
tests required several months of inhaled steroid treatment to show an effect [92, 93]. Treatment
adjustment in children with moderate asthma, based on methacholine bronchoprovocation tests, did not
result in a reduction in the percentage of symptom-free days but led to higher pre-bronchodilator FEV1 as
compared with a strategy based on symptom score only [94].
Methacholine bronchoprovocation tests may have a role in predicting later active asthma, as shown in a
birth cohort study between 10 and 16 years of age [95]. In general practice moderate and severe BHR to
methacholine could not be predicted by routinely available clinical and environmental information in the
majority of children [96]. Similarly, several studies revealed poor correlation between reported
exercise-related respiratory symptoms and the results of specific exercise testing [97].
In summary, the evidence shows that routine assessment of BHR is not useful in children with asthma;
however, there may be a place for BHR assessments in children with possible exercise limitations, poor
symptom perception and those not responding to their current treatment or with atypical asthma
symptoms. The role of indirect provocation agents such as mannitol and AMP in asthma monitoring
needs attention in longitudinal studies.
Markers of inflammation
Noninvasive biomarkers for monitoring inflammation in children are available, but their role and
usefulness in routine clinical practice to monitor and guide therapy is unclear. The selection of an
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appropriate inflammatory marker must take several factors into consideration including safety,
reproducibility, repeatability, sensitivity to treatment, and overall clinical utility.
Exhaled nitric oxide fraction
The best studied biomarker in asthma is FeNO, which has been reported to reflect both airway and tissue
eosinophilia. FeNO can be measured noninvasively, and is an extremely attractive technique for use in
children. The measurement of FeNO has been standardised for clinical use in a joint guideline from the ATS
and ERS [98]. The conventional chemiluminescence FeNO analyser, the hand-held device and offline FeNO
measurements have been shown to produce similar results in children older than 5 years of age with a
success rate of >70% and with an overall coefficient of repeatability of around 1.6–3.2 ppb [99–104]. A low
FeNO (<20 ppb) in children with asthma not treated with ICSs indicates that eosinophilic inflammation and
responsiveness to corticosteroids are less likely. FeNO values between 20 and 35 ppb are intermediate and
should be interpreted cautiously, while high values above 35 ppb are indicative of eosinophilic inflammation
[105, 106]. Currently, there is no international consensus on using age- and height-adjusted normal values
or adjusting for atopy [105, 107]. There are many additional factors associated with minor changes in FeNO,
such as treatment compliance, diet, allergen exposure, active and passive tobacco smoke exposure, and
diurnal variability. Therefore, small changes in FeNO (i.e. <10 ppb) may be clinically irrelevant.
A FeNO level of >49 ppb 4 weeks after stopping ICSs was found to predict asthma relapse with a sensitivity
of 71% and specificity of 93% [108]. In another study, FeNO and the percentage of sputum eosinophils
were both significant predictors of failed ICS reduction in clinically stable children with mild-to-moderate
asthma [109]. Two other studies failed to show any significant utility of FeNO in predicting exacerbations
in children undergoing ICS tapering [110, 111].
Most studies investigating the utility of FeNO to guide treatment have used a combination of FeNO with
other measures of asthma control, rather than FeNO alone. FeNO-guided treatment in children with asthma
did not show a difference between the groups in terms of the cumulative dose of ICSs (sum of doses at
each visit), but there was a significant decrease in BHR in the FeNO group [112]. In another study
FeNO-guided treatment resulted in higher expiratory flow at 50% of the predicted FVC compared with the
symptom-guided group [113]. There were no significant differences in any of the other secondary
outcomes: FeNO, FEV1, number of exacerbations, symptom control, or use of short acting β-agonists [113].
In the study by SZEFLER et al. [114] no differences were shown between groups looking at days with asthma
symptoms, days of school missed, asthma control test score, courses of oral corticosteroids, FEV1, or FeNO
levels. The dose of ICS was nonsignificantly higher in the FeNO group. Daily measures of FeNO were
compared with symptoms to guide treatment changes in children [115]. Both treatment strategies resulted
in a significant improvement in symptom-free days and quality of life, and a reduction in ICS dose, but
neither approach was superior. Studies which have incorporated FeNO into management algorithms have
used many different protocols, not only in terms of the frequency of measurements but also the inclusion
of other indices of asthma control. The results were variable with only some showing significant results,
but the outcome measures were not consistent across studies.
An increasing amount of information is available relating to the utility of FeNO assessments in younger
children, and recently, normative data for FeNO in infants has been reported [116]. In children with preschool
wheeze, levels of FeNO were higher in those with current symptoms or atopy compared with controls [117,
118]. Although anti-inflammatory therapy has been shown to reduce FeNO in wheezy preschool children,
there are no published data on its utility in monitoring control, adjusting therapy or in predicting
exacerbations [63, 64, 119–121]. Some data imply that elevated FeNO in preschool children is associated with
later asthma [122–124]. Elevated FeNO predicted decline in lung function in infants with recurrent wheezing,
and the risk of future wheezing in both healthy neonates and wheezy infants [125, 126]. FeNO does not seem
to correlate well with lung function in early childhood, but it does correlate with BHR [127, 128].
Taken together, based on current evidence FeNO is not useful for routine monitoring of children with
asthma, although most task force members use FeNO in children with difficult or uncontrolled asthma
especially in specialist centres. Clinical trials that assess the utility of FeNO in adjusting treatment or in
predicting exacerbations in preschool children have not been performed. It is still unclear what represents
a significant change in FeNO in a longitudinal setting.
Sputum analysis
Analysis of induced sputum cytology is a partially noninvasive tool that allows assessment of inflammatory
cells, such as eosinophils and neutrophils, as well as inflammatory mediators in supernatants.
Performance of sputum induction and sample processing have been standardised for use in children and is
well described by ERS recommendations [129]. Sputum induction has been shown to be safe in asthmatic
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children, regardless of disease severity, and feasibility is 80–85% in children between 6 and 17 years of age
[130, 131]. The methodology has not yet been standardised in preschool children.
The percentage of eosinophils is the most frequently used marker in clinical studies. In a prospective open
label clinical study in 40 children with mild-to-moderate asthma reducing ICS was successful in all
children who had no eosinophils in induced sputum before the reduction was undertaken. and induced
sputum eosinophils ⩾2% had a sensitivity of 63.6% and a specificity of 75.7% for predicting failed
reduction [109]. Eosinophils in induced sputum were significantly higher in children with stable asthma
who experienced exacerbations on reducing ICSs [132]. In severe asthmatic children a tailored intervention
based on sputum eosinophils did not significantly reduce overall asthma exacerbations or improve asthma
control when compared with conventional management based on clinical symptoms and lung function
[130]. In contrast to adults, children with difficult asthma responded to high-dose corticosteroids even in
the absence of sputum eosinophilia [133]. Therefore, detection of a non-eosinophilic sputum phenotype in
isolation does not mean clinical ineffectiveness of corticosteroids. Longitudinal assessments of sputum
eosinophils in children with severe and mild-to-moderate asthma suggest inflammatory phenotypes are
not stable over time, even without any intervening changes to therapy or in the clinical disease [130].
For now, the evidence suggests that sputum induction is not useful to monitor asthma in routine clinical
practice. However, for specific patients in specialised tertiary centres sputum eosinophils may be helpful
when making difficult treatment decisions.
Exhaled breath condensate
Exhaled breath condensate (EBC) analysis has become an increasingly used and promising method in
research, as a wide number of inflammatory mediators can be measured in EBC. It is a simple, well
tolerated and safe method, even in children with severe asthma, and is feasible in 100% of children over
4 years of age [134]. Children with asthma can be discriminated from healthy controls with EBC analysis
[135, 136]. However, although the method is simple, it can be influenced by a number of technical issues,
which can affect the final results. Despite the publication of a joint ATS/ERS task force document on
methodological considerations, many questions are not yet properly resolved [137]. EBC collection in
preschool children is of particular interest as the measurement of selected exhaled markers may allow
distinction between different phenotypes of wheezing [137–139]. However, the collection procedure in
children younger than 4 years of age may be more difficult due to the lower level of cooperation and
smaller amounts of EBC. Nevertheless, its feasibility in this age group has been demonstrated using
customised devices [120, 140].
Assessment of markers of oxidative stress in the airway makes it possible to monitor otherwise neglected
indicators of disease control. 8-isoprostane levels in EBC distinguished children with stable and unstable
asthma, independent of treatment with ICS [141]. Hydrogen peroxide was related to asthma control in a
group of asthmatics above 12 years of age [142]. In a large study, FeNO, 8-isoprostane, interferon-γ and
interleukin-4 were related to asthma control, and FeNO, 8-isoprostane, nitrate and nitrite in EBC better
indicated the degree of asthma severity [143]. More recently, KOSTIKAS et al. [144] focused on EBC pH as a
potential indicator of asthma control in a group of nearly 250 asthmatics grouped according to their level
of control as defined by Global Initiative for Asthma guidelines [145]. EBC pH is known to be low during
exacerbations, with normalisation after adequate treatment, and is related to disease severity [146, 147].
The measurement of EBC pH may be the most easily achievable measurement from EBC in a clinical
setting since it can be performed onsite with relatively simple methods. Due to methodological issues and
the lack of clinical trials of EBC in the monitoring of asthma, to date, EBC does not play a role in the
monitoring of asthma in children.
Conclusions
The lack of proper randomised controlled or large longitudinal studies makes it difficult to establish the
role of measuring lung function, BHR and airways inflammation in asthma management in children.
The regular measurement of FEV1 using office based spirometry is considered useful. However, other lung
function measurements including the assessment of BHR and airways inflammation may be reserved for
selected children with exercise limitations, poor symptom perception or with atypical asthma symptoms
and difficult or uncontrolled asthma, and performed on a higher specialty level.
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